{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-lower-men/prescribing-information/pivmecillinam/","result":{"pageContext":{"chapter":{"id":"926ae109-9068-515c-a20f-c9cc8b27eb3b","slug":"pivmecillinam","fullItemName":"Pivmecillinam","depth":2,"htmlHeader":"<!-- begin field f02391a1-995f-488e-91b8-a9a100ac52ee --><h2>Pivmecillinam</h2><!-- end field f02391a1-995f-488e-91b8-a9a100ac52ee -->","summary":"","htmlStringContent":"<!-- begin item 616e42eb-2267-4be6-809b-a9a100ac52a9 --><!-- end item 616e42eb-2267-4be6-809b-a9a100ac52a9 -->","topic":{"id":"335f7066-6009-52c3-bb1e-bb68e732e41f","topicId":"933b760e-86fa-4ba1-b937-3c052be97e83","topicName":"Urinary tract infection (lower) - men","slug":"urinary-tract-infection-lower-men","lastRevised":"Last revised in November 2018","chapters":[{"id":"a1f0f874-afae-5abc-bfc0-b8aff4687b8d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"722a30e1-802e-50da-aeb2-55a320f811e0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"54bfd7d0-4d24-5c97-b344-6dc7fe0500bf","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d780254d-b3a6-5120-a061-adbfa9d6c3d3","slug":"changes","fullItemName":"Changes"},{"id":"ded6008d-05b8-54a3-9be7-e1f9c635b466","slug":"update","fullItemName":"Update"}]},{"id":"281305b2-29ee-5ee3-879d-2a1c6115b107","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"28ce53d8-a9de-582e-b21f-63a49c9518b7","slug":"goals","fullItemName":"Goals"},{"id":"80a08351-02e8-5bf8-9865-b1f745f759f9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c65e1ea0-2e57-5742-8d13-e19bbdabcf5b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7c3a6d64-9cf2-5b7f-8c66-ac2aa0dab8b9","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"edc3c38c-1e69-5da3-8da7-174dd323fee3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a235fb13-94fa-5fa1-ac15-eae46288950c","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f1cf9c73-1a32-5912-8f20-a511a2baa05c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"423dc347-3ec3-514e-bd33-486d46645934","slug":"definition","fullItemName":"Definition"},{"id":"57c35511-4b16-5330-9634-f12fd1accf63","slug":"causes","fullItemName":"Causes"},{"id":"479b7fa1-3b50-51c3-89ac-1373a3aec46a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c6d01476-282e-5662-8378-40f864eedc0e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"dc3e67c4-09a3-557a-b9d1-7bd1b9692fd3","slug":"complications","fullItemName":"Complications"}]},{"id":"a4c4a87e-e501-53b8-bdd5-15185f853016","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"61ab2e56-53dc-5875-a0bc-41dc08a4b6b8","slug":"suspecting-a-urinary-tract-infection","fullItemName":"Suspecting a urinary tract infection"},{"id":"3f5567ff-0ab4-5228-80d9-6b8addad17e0","slug":"diagnosing-a-urinary-tract-infection","fullItemName":"Diagnosing a urinary tract infection"},{"id":"e65bf3d7-aefc-572c-bf7b-6eb6573d7fb6","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"923818be-e371-5af0-91a7-c470d34dac3c","fullItemName":"Management","slug":"management","subChapters":[{"id":"e3d61967-efe7-54fc-acbd-2e51935ca714","slug":"lower-uti-in-men","fullItemName":"Scenario: Lower UTI in men"},{"id":"f0357d1a-f5ca-5139-ac96-98e285b29c36","slug":"recurrent-uti-in-men","fullItemName":"Scenario: Recurrent UTI in men"},{"id":"88bc8e33-1e01-5b50-b9c2-362bd372238f","slug":"uti-in-men-with-an-indwelling-catheter","fullItemName":"Scenario: UTI in men with an indwelling catheter"}]},{"id":"61acfbd9-7949-528b-b893-b894f9cd6a39","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0998f6ff-17aa-58cd-8188-2fe8d30e2a63","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"0b85e5c6-7cc0-58a2-8889-5c211efc01d6","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"675b98e1-e1fa-59e0-89d1-0558968a78ba","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"926ae109-9068-515c-a20f-c9cc8b27eb3b","slug":"pivmecillinam","fullItemName":"Pivmecillinam"}]},{"id":"29b9ddff-7312-54b1-9eae-eefca43a368d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"463fe0f7-80e5-5fcd-9f1c-9c1f76f10f30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a4e1c5ad-c809-5d8c-ae1c-d37b4f97dd8c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ac4b6d54-2a63-5545-ad06-0abbe7f6354e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1b0a3ea0-682b-5ab3-ae72-bdc7fd586fce","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f7d5ea54-f1b1-59b5-9856-d52f1d73534a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f847f977-daef-5c70-8aa1-eeaf86d9cce7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"235f01e6-f3e2-5784-a197-3b4a11d45527","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"61acfbd9-7949-528b-b893-b894f9cd6a39","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"73f9b898-c421-56db-967f-b8ad6a90d44b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f8606e47-1830-4a3c-ac3a-a9a100ba3fb3 --><h3>Contraindications and cautions</h3><!-- end field f8606e47-1830-4a3c-ac3a-a9a100ba3fb3 -->","summary":"","htmlStringContent":"<!-- begin item 9d149fa1-2b4c-4e58-9833-a9a100ba3f4d --><!-- begin field 681edeab-4f50-41fd-806e-a9a100ba3fb3 --><ul><li><strong>Do not prescribe pivmecillinam in people with:</strong><ul><li>A true penicillin allergy — allergic reactions to penicillins occur in 1–10% of exposed individuals. Anaphylactic reactions occur in fewer than 0.05% of treated patients.<ul><li>Gastrointestinal adverse effects alone (for example nausea, vomiting, or diarrhoea) do not constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li></ul></li><li>Acute porphyrias.</li><li>Carnitine deficiency.</li><li>Gastrointestinal obstruction.</li><li>Oesophageal strictures. </li></ul></li><li><strong>Prescribe pivmecillinam with caution to people:</strong><ul><li>With hypersensitivity to cephalosporins.</li><li>Taking valproic acid, or valproate concurrently, or any other medication liberating pivalic due to increased risk of carnitine depletion.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">BNF 76, 2018</a>] </p><!-- end field 681edeab-4f50-41fd-806e-a9a100ba3fb3 --><!-- end item 9d149fa1-2b4c-4e58-9833-a9a100ba3f4d -->","subChapters":[]},{"id":"9ab18798-5ce3-57b5-9e93-f90ca7a4a9a5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 31c3fd3a-545a-49d8-b95a-a9a100ba51db --><h3>Adverse effects</h3><!-- end field 31c3fd3a-545a-49d8-b95a-a9a100ba51db -->","summary":"","htmlStringContent":"<!-- begin item 05b2b687-459e-4bac-bafa-a9a100ba5198 --><!-- begin field d33fbb06-10f6-42f9-85d4-a9a100ba51db --><ul><li>Common adverse effects include: <ul><li>Diarrhoea. </li><li>Nausea.</li><li>Vulvovaginal fungal infection.</li></ul></li><li>Uncommon adverse effects include:<ul><li>Dizziness.</li><li>Fatigue. </li><li>Gastrointestinal discomfort/disorders.</li><li>Headache.</li><li>Oral ulceration.</li><li>Skin reactions.</li><li>Thrombocytopenia.</li><li>Vertigo.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">BNF 76, 2018</a>]</p><!-- end field d33fbb06-10f6-42f9-85d4-a9a100ba51db --><!-- end item 05b2b687-459e-4bac-bafa-a9a100ba5198 -->","subChapters":[]},{"id":"475c9a59-30fc-55fb-9a73-2aecb669f2ea","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field cf678ef0-c7f4-4473-b485-a9a100ba6150 --><h3>Drug interactions</h3><!-- end field cf678ef0-c7f4-4473-b485-a9a100ba6150 -->","summary":"","htmlStringContent":"<!-- begin item 6e5d08e8-9fb7-4e12-9419-a9a100ba611f --><!-- begin field a710c77d-31f5-44eb-a9b6-a9a100ba6150 --><ul><li><strong>Methotrexate</strong> — pivmecillinam may reduce methotrexate clearance, causing an increased risk of toxicity.<ul><li>Monitor methotrexate levels more closely. Consider twice-weekly platelet and white cell counts for two weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li><li><strong>Oral anticoagulants (warfarin, phenindione)</strong> — INR may be increased. Monitor the international normalized ratio (INR) closely during concomitant use. Dosage adjustments may be necessary.  </li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of amoxicillin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Valproate </strong>— concurrent treatment with valproic acid, valproate or other medication liberating pivalic acid increase the risk of carnitine depletion. Avoid concurrent use. If this is not possible, monitor closely. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-men/references/\">ABPI, 2018d</a>]</p><!-- end field a710c77d-31f5-44eb-a9b6-a9a100ba6150 --><!-- end item 6e5d08e8-9fb7-4e12-9419-a9a100ba611f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}